Charts

– Prof. Steinman’s groundbreaking research linking Epstein-Barr virus to multiple sclerosis named a runner-up for the 2022 Science Magazine Breakthrough of the Year –PALO ALTO, Calif. and MIAMI, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Prof. Lawrence Steinman,

Event theme, “MS: Going Viral” touches on the role of viruses in MS, particularly Epstein-Barr, a topic related to Company’s PAS-002 drug discovery programPALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Lawrence Steinman, Pasithea’s Chairman and

Prestigious award presented by Society for Brain Mapping & Therapeutics (SBMT) and the World Brain Mapping FoundationPALO ALTO, Calif. and MIAMI, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Prof. Lawrence Steinman, Pasithea’s Chairman and National Academy of Scien

-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023 -- MIAMI BEACH, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for Central Nervous System (CNS) disorders, today announced its contract with WuXi STA, a subsidiary of WuXi AppTec, to manufacture the active pharmaceutical ingredie

Gainers Quotient (NASDAQ:QTNT) stock rose 35.8% to $0.33 during Wednesday's after-market session. This security traded at a volume of ...

Gainers Cue Health (NASDAQ:HLTH) shares rose 13.3% to $2.73 during Thursday's after-market session. The company's market cap stands at ...

MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced the final results of the Special Meeting of Stockholders (“Special Meeting”) held on December 9, 2022. According to the certified voting results provided by the Independent Inspector of Elections, a significant ma

MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced that it has reached a comprehensive Settlement and Cooperation Agreement (“the Agreement”) with Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital,

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who are collectively the largest external stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement recommending stockholders vote on the WHITE proxy card to remove the Company’s Board of Directors (the “Board”) at the upcoming Special Meeting of Stockholders (the “Special Meeting”) scheduled for Friday, December 9th, 2022:

PAS-003 is a first in class monoclonal antibody targeting Alpha 5 Beta 1 integrin as a treatment for amyotrophic lateral sclerosis (ALS) and other neuroinflammatory-driven CNS diseasesMIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Lawrence Steinman, Pasit

MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (“CNS”) disorders, today announced that it has postponed its Special Stockholder Meeting (the “Special Meeting”) originally scheduled for November 29, 2022 to allow additional time for stockholder voting proxies (the “Notice”). The Special Meetin

When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no ...

Pasithea’s Chairman, Prof. Lawrence Steinman, to be Awarded Honorary Doctorate by University of Buenos AiresMIAMI BEACH, Fla., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will present preclinica

Investor group comprisingCamac Partners LLC,Concord Investment Partners Ltd, andLeonite Capital ...

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the below statement regarding the Company's recently announced dilutive acquisition of AlloMek Therapeutics, LLC (“AlloMek”). As a reminder, the Investor Group has successfully requisitioned Pasithea’s Board of Directors (the “Board") to call a Special Meeting of Stockholders (the “Special Meeting”).

-- Expands CNS Product Portfolio with Addition of CIP-137401, a Macrocyclic, Next-Generation MEK Inhibitor -- Plans to File IND Application with the FDA to Enter the Clinic in 2H 2023 -- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) -- Management to Host an Investor Webcast Today at 9 a.m. ET MIAMI BEACH, Fla., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on

Pasithea Therapeutics Corp(NASDAQ: KTTA) has acquiredAlloMek Therapeutics LLC, a privately-held biotechnology ...

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

No action required by stockholdersMIAMI BEACH, Fla., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders, today announced that Camac Partners, LLC, Camac Capital, LLC, Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Eric Shahinian, David Delaney, and Avi Geller (collectively, the

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today announced that they sent the below letter to the Company’s Board of Directors.

NEW YORK & TORONTO, September 28, 2022--Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who are collectively the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), today announced that they sent the below letter to the Company’s Board of Directors.

Mr. Novak brings over 30 years of board and management experience at innovative life sciences companiesMIAMI BEACH, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (“CNS”) disorders, today announced that Alfred J. Novak was appointed to its Board of Directors (the “Board”). Mr. Novak replaces Dr. Y

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are one of the largest stockholders of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today announced that the Investor Group has received sufficient support from its fellow stockholders to request the call of a Special Meeting of Stockholders (the “Special Meeting”). Accordingly, the Investor Group has formally commenced the process of calling the Special Meeting and issued the following statement:

Gainers Nuwellis (NASDAQ:NUWE) shares rose 61.9% to $1.02 during Wednesday's pre-market session. The market value of ...

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 12.9% to $4.38 during Tuesday's pre-market session. The ...

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are one of the largest stockholders of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the following letter to their fellow stockholders:

Pasithea Therapeutics Corp(NASDAQ: KTTA) has announced results from a preliminary preclinical proof of concept study of PAS002, ...

An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That ...

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are one of the largest stockholders of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the following open letter to their fellow stockholders:

Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA ...

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotech company looking for new treatments for psychiatric and neurological disorders, ...

Gainers Biofrontera (NASDAQ:BFRI) shares increased by 18.5% to $2.24 during Friday's after-market session. Today's trading volume for ...

Amyotrophic lateral sclerosis (ALS) is a rare but painful and fatal disease that slowly shuts down all voluntary movements in the body, ...

Pasithea Therapeutics Corp. (NASDAQ: KTTA) recently announced the availability of an AUD $1 million (USD $694,000) drug development ...

-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction -- -- Provides approximately U.S. ...

Pasithea Therapeutics Corp. (NASDAQ: KTTA) is a biotech company with a goal of investigating novel drug treatments to provide more ...

Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the "Investor Group" or "we"), who together are the largest stockholder of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the following statement regarding the Company's dilutive and reactionary acquisition of Alpha-5 integrin, LLC (“Alpha-5”):

Pasithea Therapeutics Corp(NASDAQ: KTTA) has acquiredAlpha-5 integrin LLC, a privately-held preclinical-stage company ...

On Tuesday, 123 stocks made new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company by ...

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not ...

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not ...

Image sourced from Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not ...

Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational ...

Photo by Maxim Hopman on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and ...

Pasithea Therapeutics Corp (NASDAQ: KTTA) has partnered with Glimpse Group Inc (NASDAQ: VRAR), a Virtual Reality and Augmented Reality ...

Photo by Sydney Sims on Unsplash This post contains sponsored advertising content. This content is for informational purposes only ...

Image by Christina on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and ...